Lv7
4940 积分 2021-06-08 加入
In vivo CAR T cells move into clinical trials
3天前
已完结
The next-generation CAR-T therapy landscape
6天前
已完结
Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety
9天前
已完结
Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety
9天前
已关闭
Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety
9天前
已关闭
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
11天前
已完结
Chimeric antigen receptor T cell therapy for autoimmune disease
14天前
已完结
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
16天前
已完结
POS0030 SAFETY AND PRELIMINARY EFFICACY OF CD19 CAR-T CELL TREATMENT IN RHEUMATIC DISEASE- DATA FROM THE FIRST PART OF THE PHASE I/II CASTLE BASKET STUDY
16天前
已关闭
POS0054 AN OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY TO EVALUATE RELMACABTAGENE AUTOLEUCEL, THE CD-19 DIRECTED CAR-T CELL THERAPY, FOR ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS IN CHINA
16天前
已完结
皖公网安备34019202002308
